Randomized Evaluation of Redo Ablation Procedures of Atrial Fibrillation With FIRM Guided Procedures

NCT ID: NCT02799043

Last Updated: 2024-09-19

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

269 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-06-30

Study Completion Date

2020-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A prospective, multicenter, randomized study to assess the safety and effectiveness of FIRM-guided procedures in conventional "redo" RF ablation procedures for the treatment of persistent and paroxysmal atrial fibrillation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The hypothesis of this study was that Focal Impulse and Rotor Modulation (FIRM) guided procedures will eliminate the source of clinical arrhythmias in subjects with clinical indications for repeat AF ablation procedures.

This study is a prospective, multicenter, randomized, controlled study to assess the safety and effectiveness of FIRM procedures followed by ablation including pulmonary vein isolation versus a standard conventional procedure including pulmonary vein isolation for the redo-treatment of persistent or paroxysmal atrial fibrillation after one failed previous pulmonary vein isolation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Persistent Atrial Fibrillation Paroxysmal Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard PVI

Standard catheter ablation including pulmonary vein isolation (PVI) procedure.

Group Type ACTIVE_COMPARATOR

Standard PVI

Intervention Type PROCEDURE

Standard PVI procedure without FIRMap.

FIRM-guided Procedure and PVI

FIRM-guided procedure followed by PVI.

Group Type EXPERIMENTAL

FIRM-Guided Procedure and PVI

Intervention Type PROCEDURE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Standard PVI

Standard PVI procedure without FIRMap.

Intervention Type PROCEDURE

FIRM-Guided Procedure and PVI

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Pulmonary vein isolation Ablation Arrhythmia Atrial fibrillation Mapping Pulmonary vein isolation Atrial fibrillation Mapping FIRMap

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Experiencing at least one (1) documented episode of spontaneous persistent or paroxysmal atrial fibrillation during the last 3 months by rhythm strip/ECG.
* One (1) previous AF ablation (PVI-only - any technology) after Jan-01-2013, but NOT within the last 3 months.
* Left atrial diameter \< 6.0 cm via transthoracic echo or transesophageal echo; or \<6.5 cm via CT or MRI with 6 months prior to the procedure.
* Sustained spontaneous or induced AF (\>5 min uninterrupted).

Exclusion Criteria

* Presence of structural heart disease with clinical significance
* NYHA Class IV
* Ejection fraction \< 35%
* Previous AF ablation within the last 3 months
* ASD closure device, LAA closure device, prosthetic mitral or tricuspid valve, or permanent pacemaker.
* History of myocardial infarction (MI) within the past three (3) months
* Atrial clot/thrombus noted within 72 hours of the procedure
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Abbott Medical Devices

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Vivek Reddy, MD

Role: PRINCIPAL_INVESTIGATOR

MOUNT SINAI HOSPITAL

Stefan G. Spitzer, MD

Role: PRINCIPAL_INVESTIGATOR

Praxisklinik Herz und Gefäße Dresden, Germany

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Arizona Heart Rhythm Research Cente

Phoenix, Arizona, United States

Site Status

Ventura Cardiology Consultants

Ventura, California, United States

Site Status

Broward Health

Fort Lauderdale, Florida, United States

Site Status

St. Vincent's HealthCare

Jacksonville, Florida, United States

Site Status

Loyola University

Chicago, Illinois, United States

Site Status

Northwestern University - Bluhm Cardiovascular Institute

Chicago, Illinois, United States

Site Status

Johns Hopkins Hospital

Baltimore, Maryland, United States

Site Status

Englewood Hospital and Medical Center

Englewood, New Jersey, United States

Site Status

Ohio State University

Columbus, Ohio, United States

Site Status

University of Pennsylvania Health System

Philadelphia, Pennsylvania, United States

Site Status

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

Site Status

Virginia Heart

Falls Church, Virginia, United States

Site Status

University Hospital of Antwerp

Antwerp, Flanders, Belgium

Site Status

Klinikum Coburg

Coburg, Bavaria, Germany

Site Status

Furth Medical Clinic for Heart and Lung Diseases

Fürth, Bavaria, Germany

Site Status

The Dr. Müller Kliniken

Munich, Bavaria, Germany

Site Status

Kardiologische Gemeinschaftspraxis am Park Sanssouci

Potsdam, Brandenburg, Germany

Site Status

Kardiocentrum Frankfurt

Frankfurt, Main, Germany

Site Status

Leipzig Heart Institute GmbH

Leipzig, Saxony, Germany

Site Status

Luebeck University Heart Center

Lübeck, Schleswig-Holstein, Germany

Site Status

Ruhr University Bochum - Heart and Diabetes Center North Rhine-Westphalia

Bad Oeynhausen, , Germany

Site Status

UKB (Unfallkrankenhaus Berlin)

Berlin, , Germany

Site Status

Praxisklinik Herz und Gefäße Dresden

Dresden, , Germany

Site Status

Medical Center Rotterdam (Erasmus MC)

Rotterdam, South Holland, Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Belgium Germany Netherlands

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

REDO-FIRM

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.